The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapyAlessandro Rambaldi, Corrado Tarella, Anna Maria Barbui et al.|American Journal of Hematology|2013Cited by 65
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term SurvivalCorrado Tarella, Alessandro Rambaldi, Angela Gueli et al.|PLoS ONE|2014Cited by 26
The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without RituximabAlessandro Rambaldi, Corrado Tarella, Cristina Boschini et al.|Blood|2012Cited by 3